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Abstract
The K-RAS oncogene is widely mutated in human cancers. Activating mutations in K-RAS give rise to constitutive
signalling through the MAPK/ERK and PI3K/AKT pathways promoting increased cell division, reduced apoptosis and
transformation. The majority of activating mutations in K-RAS are located in codons 12 and 13. In a human
colorectal cancer we identified a novel K-RAS co-mutation that altered codons 19 and 20 resulting in transitions at
both codons (L19F/T20A) in the same allele. Using focus forming transformation assays in vitro , we showed that
co-mutation of L19F/T20A in K-RAS demonstrated intermediate transforming ability that was greater than that of
individual L19F and T20A mutants, but less than that of G12D and G12V K-RAS mutants. This demonstrated the
synergistic effects of co-mutation of codons 19 and 20 and illustrated that co-mutation of these codons is
functionally significant.
Findings
Mutations in RAS family genes occur in approximately
20-30% of all human cancers, with mutations in the
K-RAS gene comprising ~80% of these mutations [1].
K-RAS mutations have been documented in the majority
of human cancer types with pancreatic (~90% of these
cancers) and colorectal (~40%) cancers demonstrating the
highest incidence of mutations in this gene [2,3]. K-RAS
codons 12 and 13 are the most common sites of oncogenic
activation with over 90% of documented mutations being
found in these codons [4]. Amino acid alterations at these
codons, which encode amino acids adjacent to the GDP/
GTP binding pocket, reduce or abolish GTPase activity of
K-RAS after GAP binding and lock the protein in an
active, GTP-bound state [5]. Codons 12 and 13 in wildtype
K-RAS both encode glycine residues. The incorporation of
other amino acids, most commonly aspartate and valine at
codon 12 and aspartate at codon 13 [6], brings about pro-
jection of larger amino acid side chains into the GDP/GTP
binding pocket of the protein, interfering with the geome-
try of the transition state in which GTP hydrolysis is cata-
lysed [7]. Mutations in codons 61 and 146 have also been
described to be oncogenic in K-RAS, although mutations
at these positions occur at a much lower prevalences (<5%
of total K-RAS mutations) than codon 12 and 13 muta-
tions [4]. Activation of RAS has several effects on rodent
cells in vitro, including the establishment of a transformed
phenotype with anchorage independent growth in soft
agar, transformed focus formation, as well as tumour for-
mation following injection into animals [8-10]. Our pre-
vious mouse model studies have shown that induced
expression of mutant K-RAS accelerates intestinal ade-
noma formation in vivo on both a mutant Apc background
and a Msh2-null background, increases proliferation, mod-
ulates apoptosis and alters gene expression patterns
[11-15]. In this study, we identify a novel double mutation
outside of codons 12 and 13, recoding K-RAS codon 19
from leucine to phenylalanine (L19F) and codon 20 from
threonine to alanine (T20A), in a colorectal cancer and we
demonstrate that it causes transformation in vitro and is
therefore a rare, but functionally significant co-mutation
of K-RAS.
Sequencing of exons 1 and 2 of K-RAS in a panel 186
colorectal adenocarcinoma samples, obtained as part of
the European Prospective Investigation into Cancer and
Nutrition (EPIC) Norfolk study cohort, identified 41 can-
cers harbouring mutations in K-RAS [16]. Forty of these
mutations were located in codons 12 or 13, however, one
sample demonstrated the presence of double mutant
peaks, one at the third position of codon 19 (G > T giving
rise to a leucine to phenylalanine (L19F) amino acid
change) and the other at the first position of codon 20
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(A > G giving rise to a threonine to alanine (T20A)
change) (Figure 1). In order to assess if both base changes
were present in the same allele we cloned and sequenced
individual PCR amplicons of K-RAS exon 1 harbouring
the L19F/T20A mutations. Analysis of sequencing traces
from individual bacterial clones identified solely double
mutant (L19F/T20A) alleles (Figure 1), thus confirming
the presence of both mutations on the same allele. In
order to confirm the somatic nature of both elements of
this co-mutation, non-cancerous DNA from the blood of
the same individual was sequenced. Blood samples were
obtained upon the volunteer’s enrolment into the initial
EPIC study. Following tumour development, both blood
and tumour tissue were made available for analysis and
processed for DNA extraction [16]. Sequencing of K-RAS
exon 1 in blood DNA demonstrated only the presence of
wildtype alleles, confirming that neither of the DNA
sequence changes giving rise to the L19F or the T20A
amino acid changes were germline polymorphisms.
Missense mutations of K-RAS codon 20 in human
cancers have not been previously reported, however,
mutations giving rise to phenylalanine incorporation
into K-RAS codon 19 have been described previously in
seven individual human colorectal cancers, a single
human lung adenocarcinoma sample and a single lym-
phoblastic leukaemia [17-20]. No observations of a dou-
ble mutation giving rise to both L19F and T20A amino
acid alterations have been described previously. As such,
the observation in our study of double mutant peaks
giving rise to L19F/T20A missense co-mutations at
codons 19 and 20 of K-RAS describes a previously unre-
ported change in this gene.
A series of full length human K-RAS isoform B cDNA
sequences were designed and synthesised containing
either G12V, G12D, L19F, T20A, combined L19F/T20A
or wildtype sequences and these were cloned into
pBABE-puro expression vector plasmids for transfection
into mouse NIH3T3 cells for focus forming assays (see
Additional File 1). Transfection of K-RAS cDNA con-
structs containing individual L19F or T20A mutations
did not show significantly increased transformation
above that of the control cells, which were treated with
either transfection reagents but no cDNA or transfec-
tion reagents and wildtype K-RAS cDNA. However, cells
transfected with constructs containing the double muta-
tion L19F/T20A in K-RAS cDNA demonstrated signifi-
cantly increased focus formation above that of wildtype
K-RAS cDNA transfected control cells (Mann-Whitney
U test: P = 0.03; Figures 2 and 3). Additionally, the
K-RAS L19F/T20A co-mutation was shown to form
fewer foci than cells transfected with either G12D or
G12V mutated K-RAS cDNA (P = 0.02 and 0.04 respec-
tively). These data demonstrated that this L19F/T20A
co-mutation of K-RAS confers oncogenic activation cap-
able of inducing transformed focus formation to a
greater degree than single mutations at either codons 19
or 20 or wildtype K-RAS cDNA, but to a lesser degree
than codon 12 mutants of K-RAS.
It is not surprising that the T20A substitution alone was
not sufficiently oncogenic to cause focus formation as
this amino acid alteration has never been found pre-
viously in human cancers. However, the L19F substitu-
tion has been documented, albeit in a limited number of
studies, and may be expected to have some transforming
potential. One study described analysis of L19F in the
C. elegans RAS homologue let-60. C. elegans carrying
this mutation showed a temperature-sensitive multivul-
val phenotype. In a mammalian system, at body tem-
perature, H-RAS (L19F) protein had a reduced rate of
GTP hydrolysis relative to wildtype H-RAS, suggesting
that H-RAS L19F conferred an increased level of activa-
tion [21]. However, transfection of NIH3T3 cells with
human H-RAS with the incorporated L19F mutation
failed to demonstrate increased focus formation above
that of controls, a similar observation to that made here
using L19F K-RAS. A second report, however, describes
Figure 1 Dideoxysequence traces of the L19F and T20A double
mutation in K-RAS. (A) Identification of double peaks at the third
base of codon 19 and first base of codon 20 in a colorectal cancer.
This sequence trace did not determine whether both base changes
were on the same or two independent alleles. Harvesting of tumour
genomic DNA and sequencing methodology has been described in
detail elsewhere [16]. (B) Sequence trace (upper panel),
demonstrating the normal leucine and threonine codons at
positions 19 and 20 of the K-RAS sequence. Sequence trace from a
bacterial clone (lower panel) showing the appearance of the double
mutation L19F/T20A in the same allele. For cloning of tumour
derived PCR amplicons, products were ligated into TOPOBlunt
plasmids using ZeroBlunt TOPO cloning kits (Invitrogen, Paisley, UK)
according to the manufacturer’s instructions. Bacterial DNA was
then isolated using Miniprep kits (Qiagen, Crawley, UK) according to
the manufacturer’s instructions and sequenced using M13 universal
primers on a ABI3730xl Platform sequencer (Applied Biosystems,
Warrington, UK).
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L19F as causing increased cell proliferation, anchorage-
independent growth, increased tumourigenicity in nude
mice and elevated levels of RAS-GTP [17]. Additionally,
a recent analysis describing K-RAS mutations outside of
codons 12 and 13 also described mildly increased focus
formation by L19F mutants [22]. In this report the L19F
K-RAS mutation was described to induce formation of
~5 foci whereas positive controls (G12V and G12D) were
observed to develop ~80 - 90 foci. These data are not
mutually exclusive with our observations, as the mean
focus count observed here with the G12D mutant was 35
colonies per plate, thus a mild focus forming ability of
the L19F mutation may not have been detected. The
observed differences between the number of colonies
formed in the study by Smith and colleagues [22] and
those in our own assays may be due to variations in pro-
tocols used, such as the different expression vectors used
in the two analyses giving rise to different levels of tran-
scription following transfection into NIH3T3 cells and
different tissue culture plating conditions.
Our identification and analysis of the L19F/T20A dou-
ble mutation in K-RAS is the first description of this
genetic change, which confers a greater transforming
ability than individual mutations in these codons. The
rare observed frequency of this double amino acid
change giving rise to oncogenic K-RAS in human can-
cers, compared with that of the individual L19F amino
acid change, despite its increased oncogenic potential,
may be due to the lower likelihood of 2 base changes
occurring at these positions in the same allele during
cancer development.
To assess the potential structural effects of the L19F/
T20A amino acid changes we modelled their side chains
into a shortened wildtype K-RAS protein ribbon struc-
ture bound to a GTP analogue (Figure 4a). Codons 19
and 20 (shown in white in Figure 4b) are in close proxi-
mity to the GDP/GTP binding pocket of the protein.
Modelling of the mutant phenylalanine (codon 19) and
alanine (codon 20) side chains into the wildtype protein
predicted two features. First, the removal of the leucine
side chain at codon 19 and its replacement with that of
phenylalanine resulted in projection of the bulky, ringed
side chain of the newly encoded amino acid into the
main body of the protein and this may be predicted to
change the shape of the GDP/GTP pocket by steric
interference. Second, removal of the threonine side
Figure 2 Focus formation by mutated K-RAS cDNA. Methylene
blue stained transformed foci following transfection of K-RAS cDNA
expression vectors containing: (A) G12D (B) G12V (C) L19F alone (D)
T20A alone (E) L19F/T20A co-mutation and (F) wildtype sequences.
“No DNA” controls describe cells treated with transfection reagents
but no DNA. Colonies formed following transfection with the L19F/
T20A double mutant K-RAS cDNA were consistently smaller than
those formed following transfection with the codon 12 mutants.
K-RAS cDNA containing plasmids were lipofected with
Lipofectamine (Invitrogen, Paisley, UK) into NIH3T3 mouse fibroblast
cells, and seeded onto 60 mm plates at a density of 100 000 cells
per plate. The cells were grown for 14 days, with the media
replaced every 72 hours. After 14 days plates were fixed in 10%
formalin then stained with 1% methylene blue (Sigma-Aldrich,
Gillingham, UK), in 70% ethanol solution. Colonies above 3 mm in
diameter were counted and were statistically analysed using Mann-
Whitney U tests with P values of less than or equal to 0.05
considered statistically significant.
Figure 3 Quantification of focus formation by different K-RAS
mutations. Histogram of mean focus numbers obtained from focus
formation assays performed in 4 separate experiments after NIH3T3
cells were transfected with K-RAS cDNA expression vectors
containing G12V, G12D, L19F, T20A, L19F/T20A or wildtype K-RAS
sequences. Error bars represent ±SD. Full focus counts for all
transfections and all experiments and the sequences of the cDNA
constructs used for NIH3T3 cell transfection are described in
Additional File section (Additional File 1).
Naguib et al. Journal of Molecular Signaling 2011, 6:2
http://www.jmolecularsignaling.com/content/6/1/2
Page 3 of 5
chain at codon 20, with loss of its OH group and its
replacement with alanine that has a smaller aliphatic
side chain may be predicted to affect the ionic interac-
tions between nearby amino acid side chain groups
(Figure 4c &4d). The presence of changes at both
codons 19 and 20, demonstrating a higher transforming
activity than individual mutations in these codons, sug-
gests that shifting of the protein conformation due to
steric interference together with disruption of ionic
interactions within the K-RAS protein, may be responsi-
ble for generating a protein configuration capable of
providing the observed transforming activity, by interfer-
ing with the geometry of the GDP/GTP binding pocket
reducing GTP hydrolysis. Further structural studies are
required to test this proposed mechanism.
K-RAS mutations affecting codons 15 and 22 have also
been reported in human colorectal cancers [23,24].
Although the transforming ability of these specific
codon changes is yet to be confirmed, the observation
of sequence changes in human cancers affecting codons
15 and 22, as well as at co-mutation of codons 19 and
20, as described here, strongly suggests that alteration of
this region in the K-RAS protein provides a selective
growth advantage for cells which contributes to neoplas-
tic transformation.
Additional material
Additional file 1: Experimental methods and statistical testing.
Additional File 1 contains a detailed description of all experimental
methods described in this manuscript. Furthermore, complete colony
counts are available for all experiments in tabulated format.
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Figure 4 Modelling of the mutant codon 19 phenylalanine and codon 20 alanine side chains into the K-RAS protein. (A) The GDP/GTP
binding pocket of wildtype K-RAS. The white residues are codons 19 and 20. The loop on the left of the helix forms the GDP/GTP binding
pocket of K-RAS. Residues coloured blue represent the mutational hotspot codons 12 and 13. The shortened K-RAS protein structure used for
modelling was obtained from the Protein Data Bank (PDB ID:3gft) and visualised using PyMOL (http://www.pymol.org). (B) The GDP/GTP binding
pocket of wildtype K-RAS with wildtype side chains of codons 19 and 20 and a non-hydrolysable GTP analogue (used during crystallisation)
adjacent to codons 12 and 13. (C and D) Modelling of the mutant phenylalanine (codon 19) and alanine (codon 20) side chains into the K-RAS
protein, predicts projection of the bulky phenylalanine side chain into the main body of the protein and replacement of the OH containing side
chain of threonine with the small aliphatic side chain of alanine. The mutant side chains were modelled into positions of the protein which
produced the fewest conflicting Van der Waals radii and the configuration with the least steric interference with other amino acid side chains.
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